Structure-activity relationship studies and bioactivity evaluation of 1,2,3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors

Keyphrases

• Structure-activity Relationship Studies 100%
• Study Evaluation 100%
• Bioactivity Scores 100%
• Sphingosine Kinase 2 Inhibitors 100%
• 1,2,3-triazole 100%
• SphK2 100%
• Sphingosine Kinase 1 (SphK1) 60%
• Antitumor Activity 20%
• Cardiovascular Disease 20%
• IC50 Value 20%
• Inhibitory Activity 20%
• Antitumor 20%
• Bioactivity 20%
• High Selectivity 20%
• Neurological Disorders 20%
• Pharmacophore 20%
• Glioblastoma Cell Lines 20%
• Kinase Assay 20%
• New Analogs 20%
• Sphingosine-1-phosphate 20%
• High Potency 20%
• Polar Headgroup 20%
• Molecular Modeling Studies 20%
• Cancer-related Inflammation 20%
• 1,2,3-Triazole Analogs 20%
• Inflammation Disorders 20%
• ADP-Glo 20%
• Pathophysiologic Pathways 20%
• U251 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Structure Activity Relationship 100%
• Sphingosine Kinase 2 100%
• Triazole 100%
• Neoplasm 66%
• Phosphotransferase 33%
• Malignant Neoplasm 33%
• Glioblastoma 33%
• Inflammation 33%
• Adenosine Diphosphate 33%
• IC50 33%
• Sphingosine Kinase 33%
• Sphingosine 1 Phosphate 33%
• Cardiovascular Disease 33%